3 ASX shares I dream of owning at the right price

These companies look incredibly appealing in my eyes. What price would it take for me to dive in?

| More on:
a man lies on his back on grass with his eyes shut and a contented look on his face as though he is dreaming

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There are many ASX shares vying for a position in my portfolio at any single point in time. Companies that exhibit impressive revenue growth, sell incredibly valuable products/services, and are leaders in their fields.

However, as amazing as these businesses might be, many fail to meet one of the most important hurdles … the right price. More specifically, a price that is accommodative to the errors we all will inevitably make from time to time as investors.

The margin of safety is one of the most important investing principles, yet I rarely hear it discussed. This is despite it being one of the few things that can be controlled as a small shareholder. Several years of returns can be engulfed by paying too high of a price for even quality companies.

Below are three ASX shares that I believe are exceptional businesses, but trade on exceptionally high valuations.

I'd buy these ASX shares if the price was right

Objective Corporation Limited (ASX: OCL)

Objective Corp is possibly my favourite company on this list, making it into my top 10 picks for 2023. The company provides a broad range of software solutions to both the public and private sectors.

Thirty-six years on from its inception and Objective Corp is still delivering 20% year-on-year earnings growth. Another enticing trait is the company's rock-solid balance sheet, with no debt and $63.8 million in cash. Not to mention it is founder-led by Tony Walls, who holds an ownership stake of more than 65% in the company.

Unfortunately, the price-to-earnings (P/E) ratio of around 73 times offers little in the way of a margin of safety. Even if Objective's revenue grows at 20% over the next five years, most of that appears to be priced in. I'd happily add this ASX share to my portfolio if the price was more in the ballpark of $8 to $9.

Currently, it trades at $14.80.

Polynovo Ltd (ASX: PNV)

This is a company I had held previously in my portfolio but decided to remove it due to its deteriorating balance sheet.

Polynovo leverages its proprietary polymer technology for wound treatment and burns. Impressively, the company's revenue has been growing at a 62% clip in the last year, reaching $41.9 million. Though, expansion to new markets and customers is still in the early stages.

Furthermore, Polynovo has recently undertaken a $30 million institutional placement, fortifying its balance sheet once more. Though, the business is still loss-making.

The rapid revenue growth is alluring, but the industry can be competitive. For example, Avita Medical Inc (ASX: AVH) offers a burn treatment of its own that comes in a spray-on form.

Given that Polynovo is yet to prove its profitability, I'm personally holding out for a share price below $1.30. At present, shares in this ASX medical company are fetching $2.50 apiece.

CSL Limited (ASX: CSL)

I'd assume I'm not alone in dreaming of owning a piece of this Australian biotech beast.

CSL is a company that probably needs no introduction. Its expansive portfolio of intellectual property puts it on the world stage of healthcare expertise — covering antibodies, clotting agents, and HPV and flu vaccines.

The company's medical technology is hard to replicate and is usually protected by law, leading to profit margins above 20%. Additionally, the management team has demonstrated exceptional ability in making accretive acquisitions over the years.

Nonetheless, at an earnings multiple of 39 times FY25 forecast earnings for the company, CSL's valuation is a bit difficult for me to swallow. I'd personally love to add CSL to my portfolio at a price below $200 compared to its current $295.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Avita Medical, CSL, Objective, and PolyNovo. The Motley Fool Australia has recommended Avita Medical. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Opinions

Man in an office celebrates at he crosses a finish line before his colleagues.
Opinions

These stocks made my share portfolio a market-beater in 2024

Beating the market is the least important takeaway from this year.

Read more »

A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
Opinions

2 underappreciated ASX 200 shares to buy now

Investors may be undervaluing these ASX 200 shares heading into 2025, according to this expert.

Read more »

A man wearing a shirt, tie and hard hat sits in an office and marks dates in his diary.
Resources Shares

Is the BHP share price a buy? Here's my view

Is it time to dig into this beaten-up miner?

Read more »

A person holds their hands over three piggy banks, protecting and shielding their money and investments.
How to invest

I'm preparing for an ASX stock market crash in 2025

Whatever happens next year, my portfolio will be ready...

Read more »

Happy couple enjoying ice cream in retirement.
Opinions

2 ASX shares I loaded up on in November for long-term wealth

I’m excited by the dividend and capital growth potential of these stocks.

Read more »

A group of businesspeople clapping.
Opinions

My prediction for the best-performing ASX sectors in 2025

Here’s where I think the outperformers will come from.

Read more »

A family of four wearing Santa hats open presents on the beach next to a Christmas tree.
Opinions

Top ASX shares to buy before Christmas

Here are some guilt-free purchases that you can snag without battling a crowd this Christmas.

Read more »

Businessman studying a high technology holographic stock market chart.
Opinions

Where will the ASX 200 be this time next year?

Morgan Stanley has delivered its forecast for the Australian share market in 2025.

Read more »